REVIEW ARTICLE
Potential of Polyphenolic Nutraceuticals in the Management of Glioblastoma Multiforme
Swati Devendra Raysing1, *, Ashish Prakash Gorle2
Article Information
Identifiers and Pagination:
Year: 2022Volume: 3
Issue: 2
E-location ID: e250522205270
Publisher ID: e250522205270
DOI: 10.2174/2665978603666220525161010
Article History:
Received Date: 17/11/2021Revision Received Date: 02/02/2022
Acceptance Date: 10/03/2022
Electronic publication date: 22/08/2022
Abstract
Glioblastoma Multiforme (GBM) is a malignant central nervous system tumor. GBM is produced by aggressive proliferation of cells and invasion of normal brain tissue. The current conventional therapies for GBM include surgery, chemotherapy, and radiation therapies which are challenging and produce adverse effects. Thus, polyphenolic nutraceuticals are effective natural compounds for preventing and treating GBM due to their chemoprotective activity. Polyphenols are bioactive, non-nutrient plant chemicals structurally sub-divided into 5 groups; among these groups, phenolics and flavonoids are widely studied as they have lesser side effects and a more significant potential to pass the Blood-Brain Barrier (BBB). These polyphenolic nutraceuticals have the potential to advance current GBM treatment options. This review throws light on the anti-cancer efficacy of major polyphenol classes (Phenolic acid, Flavonoids, Stilbenes, Lignans) and discusses their prospective mechanisms of action in GBM.